Microbix Biosystems (MBXBF) 0.4200 $MBXBF
Microbix Revenue Grows 23% in Second Quarter
Marketwired - Fri May 15, 7:43AM CDT
Microbix Biosystems Inc. (TSX: MBX), an innovator of biological products and technologies, today reported financial results for its second quarter ending March 31, 2015.
MBX.TO: 0.48 (-0.04)
IIROC Trade Resumption - Microbix Biosystems Inc.
Newsfile Corp - Fri May 15, 7:36AM CDT
Trading resumes in:
Microbix Provides Update on U.S. VIRUSMAX Litigation
Marketwired - Fri May 15, 7:28AM CDT
Microbix Biosystems Inc. (TSX: MBX) ("Microbix" or the "Company"
, an innovator of biological products and technologies, announced today that the U.S. District Court in the Eastern District of Texas has provided its decisions on a litigation between Microbix and Novartis. In the matter of whether Novartis has infringed the 18 patent claims asserted by Microbix on its patent 7,270,990 in the United States, the court ruled in favour of Novartis, the defendant. Concerning the defendant's counterclaim seeking a declaratory judgment of patent invalidity, the court dismissed it without prejudice. All other claims and counterclaims asserted between the parties were likewise dismissed without prejudice. Court administration costs, which are not expected to be material, are the responsibility of Microbix. Both parties have the right to appeal the court's decisions.
MBX.TO: 0.48 (-0.04), NVS: 103.75 (-0.15)
IIROC Trade Halt - Microbix Biosystems Inc.
Newsfile Corp - Thu May 14, 1:15PM CDT
The following issues have been halted by IIROC:
Microbix to Present at 2015 Bloom Burton & Co Healthcare Investor Conference
Marketwired - Wed Apr 29, 3:54PM CDT
Microbix Biosystems Inc. (TSX: MBX) ("Microbix" or the "Company", an innovator of biological products and technologies, today announced that its CFO, Charles Wallace, will present an update of the Company's business at the 2015 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on Tuesday, May 5, 2015 at 3:00 p.m. Eastern Time.
MBX.TO: 0.48 (-0.04)
Microbix Signs Virology Distribution Agreement for South Korea
Marketwired - Thu Apr 02, 7:31AM CDT
Microbix Biosystems Inc. (TSX: MBX) ("Microbix" or the "Company", an innovator of biological products and technologies, announced today it has signed an exclusive distribution agreement with Kim & Friends, Inc. ("K&F". With more than 1,500 healthcare customers in South Korea, K&F is recognized for providing strong scientific and technical support. The agreement provides Microbix with improved access to the key South Korean market for its virology products.
MBX.TO: 0.48 (-0.04)
Microbix Announces First Molecular Diagnostics Agreement
Marketwired - Tue Mar 31, 8:04AM CDT
Microbix Biosystems Inc. (TSX: MBX) ("Microbix" or the "Company", an innovator of biological products and technologies, announced today that it has entered into a long-term agreement with St. Cloud, Minnesota-based Microbiologics, Inc. ("Microbiologics", a leading developer of biological controls and standards, pursuant to which Microbix will provide specialized viral material which will be incorporated into a line of full process controls, including instrument-specific sets, under Microbiologics' Helix Elite(TM) Molecular Standards brand.
MBX.TO: 0.48 (-0.04)
Microbix Lawsuit in Germany Dismissed Without Prejudice
Marketwired - Thu Mar 26, 8:29AM CDT
Microbix Biosystems Inc. (TSX: MBX) ("Microbix" or the "Company", an innovator of biological products and technologies, announced today that the Court of Dusseldorf, Germany has dismissed its VIRUSMAX(R) patent infringement lawsuit against Novartis Vaccines and Diagnostics ("Novartis" without prejudice.
MBX.TO: 0.48 (-0.04), NVS: 103.75 (-0.15)
Microbix Announces New Product Launches in Field of Molecular Diagnostics
Marketwired - Mon Mar 02, 5:42AM CST
Microbix Biosystems Inc. (TSX: MBX) ("Microbix" or the "Company", an innovator of biological products and technologies, today announced new Molecular Diagnostics ("MDx" product launches and provided an update on several important initiatives in its Virology Products business.
MBX.TO: 0.48 (-0.04)
Microbix Reports Virology Revenue Up 8% in First Quarter
Marketwired - Fri Feb 13, 7:31AM CST
Microbix Biosystems Inc. (TSX: MBX), an innovator of biological products and technologies, today reported financial results for its first quarter ending December 31, 2014.
MBX.TO: 0.48 (-0.04)
Microbix Revenue Grows 23% in Second Quarter
Marketwired - Fri May 15, 7:43AM CDT
Microbix Biosystems Inc. (TSX: MBX), an innovator of biological products and technologies, today reported financial results for its second quarter ending March 31, 2015.
MBX.TO: 0.48 (-0.04)
IIROC Trade Resumption - Microbix Biosystems Inc.
Newsfile Corp - Fri May 15, 7:36AM CDT
Trading resumes in:
Microbix Provides Update on U.S. VIRUSMAX Litigation
Marketwired - Fri May 15, 7:28AM CDT
Microbix Biosystems Inc. (TSX: MBX) ("Microbix" or the "Company"
, an innovator of biological products and technologies, announced today that the U.S. District Court in the Eastern District of Texas has provided its decisions on a litigation between Microbix and Novartis. In the matter of whether Novartis has infringed the 18 patent claims asserted by Microbix on its patent 7,270,990 in the United States, the court ruled in favour of Novartis, the defendant. Concerning the defendant's counterclaim seeking a declaratory judgment of patent invalidity, the court dismissed it without prejudice. All other claims and counterclaims asserted between the parties were likewise dismissed without prejudice. Court administration costs, which are not expected to be material, are the responsibility of Microbix. Both parties have the right to appeal the court's decisions. MBX.TO: 0.48 (-0.04), NVS: 103.75 (-0.15)
IIROC Trade Halt - Microbix Biosystems Inc.
Newsfile Corp - Thu May 14, 1:15PM CDT
The following issues have been halted by IIROC:
Microbix to Present at 2015 Bloom Burton & Co Healthcare Investor Conference
Marketwired - Wed Apr 29, 3:54PM CDT
Microbix Biosystems Inc. (TSX: MBX) ("Microbix" or the "Company"
, an innovator of biological products and technologies, today announced that its CFO, Charles Wallace, will present an update of the Company's business at the 2015 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on Tuesday, May 5, 2015 at 3:00 p.m. Eastern Time. MBX.TO: 0.48 (-0.04)
Microbix Signs Virology Distribution Agreement for South Korea
Marketwired - Thu Apr 02, 7:31AM CDT
Microbix Biosystems Inc. (TSX: MBX) ("Microbix" or the "Company"
, an innovator of biological products and technologies, announced today it has signed an exclusive distribution agreement with Kim & Friends, Inc. ("K&F". With more than 1,500 healthcare customers in South Korea, K&F is recognized for providing strong scientific and technical support. The agreement provides Microbix with improved access to the key South Korean market for its virology products. MBX.TO: 0.48 (-0.04)
Microbix Announces First Molecular Diagnostics Agreement
Marketwired - Tue Mar 31, 8:04AM CDT
Microbix Biosystems Inc. (TSX: MBX) ("Microbix" or the "Company"
, an innovator of biological products and technologies, announced today that it has entered into a long-term agreement with St. Cloud, Minnesota-based Microbiologics, Inc. ("Microbiologics", a leading developer of biological controls and standards, pursuant to which Microbix will provide specialized viral material which will be incorporated into a line of full process controls, including instrument-specific sets, under Microbiologics' Helix Elite(TM) Molecular Standards brand. MBX.TO: 0.48 (-0.04)
Microbix Lawsuit in Germany Dismissed Without Prejudice
Marketwired - Thu Mar 26, 8:29AM CDT
Microbix Biosystems Inc. (TSX: MBX) ("Microbix" or the "Company"
, an innovator of biological products and technologies, announced today that the Court of Dusseldorf, Germany has dismissed its VIRUSMAX(R) patent infringement lawsuit against Novartis Vaccines and Diagnostics ("Novartis" without prejudice. MBX.TO: 0.48 (-0.04), NVS: 103.75 (-0.15)
Microbix Announces New Product Launches in Field of Molecular Diagnostics
Marketwired - Mon Mar 02, 5:42AM CST
Microbix Biosystems Inc. (TSX: MBX) ("Microbix" or the "Company"
, an innovator of biological products and technologies, today announced new Molecular Diagnostics ("MDx" product launches and provided an update on several important initiatives in its Virology Products business. MBX.TO: 0.48 (-0.04)
Microbix Reports Virology Revenue Up 8% in First Quarter
Marketwired - Fri Feb 13, 7:31AM CST
Microbix Biosystems Inc. (TSX: MBX), an innovator of biological products and technologies, today reported financial results for its first quarter ending December 31, 2014.
MBX.TO: 0.48 (-0.04)
